anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Penumbra is the newest member of the tetraspanin superfamily of membrane proteins. A major obstacle in penumbra research has been the lack of monoclonal antibodies against the native penumbra. In this invention, we detail the establishment and characterization of monoclonal antibodies that recognize both human and mouse penumbras on living cells. Furthermore, we created chimeric mouse-human lgG1 antibodies from these mouse monoclonal antibodies. Using these antibodies, we demonstrate for the first time that penumbra is expressed on the surface of virtually all CD19+ or CD20+ B lymphocytes in blood, bone marrow, spleen and lymph nodes. In vivo, these monoclonal antibodies shrank lymphoid follicles in spleen. Thus, these antibodies establish penumbra as a novel B cell marker with a wider range of expression level than CD19 or CD20. These monoclonal antibodies pave the way for new research and potential therapeutic applications in immunology, hematology and oncology.
UFH was administered as a bolus according to standard of care for completion of PPCI per site. An ACT ≥250 s at the end of the procedure was recommended.
The first experimental group will receive supplementation with pure ALA fraction of EFA esters. 5 ml a day of OmegaRegen Original containing 2.9 g of ALA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
The present invention discloses compound saffron oil and a production technology thereof. The compound saffron oil is prepared from 1 wt. % of saffron, 7 wt. % of turmeric, 45 wt. % of turpentine, 20 wt. % of basil oil, 15 wt. % of peppermint oil, 1 wt. % of borneol and 1 wt. % of anhydrous alcohol. The production technology comprises the following steps: the saffron and the turmeric are pulverized into powder, and soaked in ethanol with the concentration of 80% for 24 hours; the soaked liquid is concentrated to obtain thick paste, and the thick paste is pulverized into powder and is dissolved in the anhydrous alcohol; finally the basil oil, the peppermint oil, the turpentine and the borneol are added and stirred uniformly, and the anhydrous alcohol is added to full dose. The present invention has the effects of alleviating pain, resisting inflammation, eliminating swelling, improving periphery microcirculations and inhibiting capillary permeability, has obvious therapeutic effect and small toxic and side effect, is widely used for treating diseases, such as traumatic injury, rheumatic ostealgia, etc., and is especially suitable for the patients on the Qinghai-Tibet plateau or in dry climatic environment.
The bioresorbable vascular scaffold (BRS) has been emerged as new therapeutic option in percutaneous coronary intervention for coronary artery disease. Although 2nd generation drug-eluting stent (DES) has enhanced the efficacy and safety of DES, However, along with the widespread use of this newer generation DES in most clinical conditions, including high-risk patients with more complicated lesion profiles, ISR has continued to be a major concern, even in the era of newer generation DES. In this regards, the concept of BRS has introduced and has showed promising results. Nevertheless, previous reports showed that even BRS has not been free from restenosis, leading target lesion revascularization up to 7.4% during 3-year follow up. Currently, previous researches which comparedsafety and efficacy of treatment options for ISR lesion showed similar clinical outcomes following 2 representative options, namely, drug-eluting balloon or drug-eluting stent. In this regards, current European Society of Cardiology/European Association for Cardiothoracic Surgery (ESC/EACTS) guidelines recommend drug-eluting balloon (DEB) and 2nd generation DES as class IA recommendations for the treatment of BMS or DES-ISR. However, all the previous reports evaluated the ISR of metallic stents, and there has been no evidence for treatment option for BRS ISR.

Therefore, the Smart Angioplasty Research Team: Safety and Efficacy of Drug-Eluting Balloon versus 2nd Generation Drug-Eluting Stent in Treatment of In-Bioresorbable Vascular Scaffold Restenosis (SMART-BRS-ISR) trial will randomly allocate patients with BRS ISR into DEB or 2nd generation DES and compare safety and efficacy of both treatment options.
Cancer-related chronic pain remains as a big challenge for cancer survivors, which significantly affects the quality of life of cancer survivors. Evidence suggests that pain is well managed through combination of pharmacological and non-pharmacological interventions. Among all non-pharmacological interventions, breathing exercise (BE) might have potential effect for chronic pain management in cancer survivors, but the evidence is sparse in current literature. Therefore, this study will follow the Medical Research Council Framework for Developing and Evaluating Complex intervention (the MRC Framework) to develop an evidence-based BE protocol to help with cancer-related chronic pain management in breast cancer survivors. The first two phases of the MRC Framework will be included in this study. In the first phase, an evidence-based method will be utilized to develop the BE intervention protocol. In the second phase, a pilot randomised controlled trial (RCT) will be conducted to examine the feasibility of study and the acceptability of the BE intervention by the participants as well as to preliminarily assess the effect of the BE on chronic pain management in breast cancer survivors. Semi-structured interviews will be conducted after the RCT to explore participants' experiences of participating in the study and practicing the BE.
The implanted infusion pump system has a fluid link (13) between the chamber (9) to hold the active substance mass and the infusion point with a unit (14) which only releases the flow path when the mass in the chamber (9) is at a pressure over a given minute pressure level. The implanted infusion pump system has a fluid link (13) between the chamber (9) to hold the active substance mass and the infusion point with a unit (14) which only releases the flow path when the mass in the chamber (9) is at a pressure over a given minute pressure level. The fluid link between the chamber (3) to hold the active substance to be applied and the infusion point is an infusion line (8), with a feed line (13) to link the mass chamber (9) to the infusion point which has an overpressure valve (14) as a slitted disk. The min. pressure for the system is 2-4 bar and pref. 2.5-3.5 bar. An Independent claim is also included for an operating mechanism with a holder to secure the syringe cylinder and an actuator to grip the syringe plunger with a drive for its operation to press the plunger into the syringe cylinder. The drive moves the actuator from a start position against a return pressure and locks it in place. On release, the return pressure restores the plunger to the initial position.
Tranexamic acid will be provided as an intravenous infusion (1g in 100mL 0.9% NaCl solution \[1% TXA\] at 5 ml/min) 20 minutes pre-operatively, followed by an additional intravenous dose of the same dosing parameters postoperatively. Oral tablet doses containing 1 g of TXA (2x 500mg tablets) per dose will be administered to the patient to be taken orally by the patient according to a standard regimen; the first tablet dose will be taken on the same day as the surgery, in the evening. The patient will then take one tablet dose three times a day for a total of five days following the surgery (one dose in the morning, one dose mid-day, and one dose in the afternoon) for a 6 day total regimen.
Venlafaxine hydrochloride extended-release capsules USP are an extended-release capsule for once-a-day oral administration that contains venlafaxine hydrochloride, a SNRI.   
Venlafaxine is designated Cyclohexanol,1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, hydrochloride or (±)-1-[α-[(dimethylamino)methyl]-p-methoxybenzyl]cyclohexanol hydrochloride and has the empirical formula of C 17H 27NO 2 HCl. Its molecular weight is 313.9. The structural formula is shown as follows:

Venlafaxine hydrochloride USP is a white or almost white powder, freely soluble in methanol and water, soluble in anhydrous ethanol and slightly soluble or practically insoluble in acetone.   
Drug release is controlled by diffusion through the coating membrane on the spheroids and is not pH-dependent. Capsules contain venlafaxine hydrochloride USP equivalent to 37.5 mg, 75 mg, or 150 mg venlafaxine. Inactive ingredients consist of ethyl cellulose, hypromellose, sugar spheres and talc. The capsule shells have the following inactive ingredients: iron oxide yellow, iron oxide red, iron oxide black, gelatin and titanium dioxide.   
The printing ink contains shellac, strong ammonia solution, black iron oxide and potassium hydroxide.   
FDA approved dissolution specification differs from the USP dissolution specification.
PURPOSE: To treat an emotional paralysis by administering an effective amount of a sedative antagonistic agent or pharmaceutically permissible salt thereof. CONSTITUTION: A relevant patient is administered with a sedative antagonistic agent (pref. a compound bearing a five-membered cyclic nucleus such as nalmefene, naloxone, naltrexone, nalbuphine or thebaine) or pharmacologically permissible salt thereof in an amount effective for transforming emotional paralysis so as to treat the patient's emotional paralysis involved in stress disorder developed after external wound or other psychopathologic lesions. Oral administration is esp. effective for this compound, its dose being 0.5-1.0 mgms.b.i.d. for the 1st one week, 1.0-5.0mgms.b.i.d. for the next one week, 5.0-10.0mgms.b.i.d., 10.0-20.0mgms.b.i.d. for the next one week, then increasing 10.0-20.0mgm each per week over the period until the patient is freed from paralytic state.
PURPOSE: Sepsis is the main cause of nonrelapse mortality, and there are no published data on applicability of supportive care protocols from high-income countries such as Sri Lanka. The aim of the study was to investigate management and mortality of neutropenic episodes among Hemato-Oncology patients.
MATERIALS AND METHODS: Retrospective analysis of clinical characteristics, management, morbidity, and mortality of neutropenic Hemato-Oncology patients presented to the Lanka Hospital Blood Cancer Centre from January 1, 2019 to December 31, 2019 was performed.
RESULTS: A total of 169 neutropenic episodes were identified; 115 (68%) of such episodes were related to chemotherapy. Acute leukemia, lymphoproliferative disorders, and plasma cell disorders accounted for 23%, 69%, and 8% of patients, respectively. The median age of patients who had sepsis was 56 years, whereas that of those who had no sepsis was 53 years (P = .49). The median time to neutropenia was 9 days for those in the sepsis group compared with 8 days in the group that had no sepsis (0.64). The median neutrophil count in the group that had sepsis was 0.06, whereas it was 0.69 in the group that had no sepsis (P ≤ .05). The median time to commencement of antibiotics was 20 minutes.
CONCLUSION: To our knowledge, this is the only documented study related to outcome and successful applicability of western supportive care protocols to Sri Lankan patients with neutropenia. In this study, we have shown that neutropenic sepsis can be successfully managed in the setting of limited resources with service development, following guidelines and staff training.
AIM: To gain a greater understanding of how compression therapy affects quality of life, this systematic review appraised existing published studies measuring the impact of compression therapy on health quality of life (HRQoL), and pain, among people with venous leg ulcers (VLU).
METHOD: Five databases were searched, and two authors extracted data and appraised the quality of selected papers using the RevMan risk of bias tool. Due to heterogeneity in the types of compression and instruments used to evaluate HRQoL, meta-analysis was not appropriate; thus, a narrative synthesis of findings was undertaken.
RESULTS: Ten studies were included, 9 RCTs and one before-after study. The studies employed nine different HRQoL tools to measure the impact of a variety of compression therapy systems, with or without an additional exercise programme, versus other compression systems or usual care, and the results are mixed. With the use of the Cardiff Cardiff Wound Impact Schedule, the SF-8 and the SF-12, study authors found no differences in QoL scores between the study groups. This is similar to one study using QUALYs (Iglesias et al., 2004). Conversely, for studies using EuroQol-5D, VEINES-QOL, SF-36 and CIVIQ-20 differences in QoL scores between the study groups were noted, in favour of the study intervention groups. Two further studies using QUALYs found results that favoured a two-layer cohesive compression bandage and the TLCCB group, respectively. Results for the five studies that assessed pain are also mixed, with one study finding no difference between study groups, one finding that pain increased over the study period and three studies finding that pain reduced in the intervention groups. All studies were assessed as being at risk of bias in one or more domains.
CONCLUSION: Results were varied, reflecting uncertainty in determining the impact of compression therapy on quality of life and pain among people with a venous leg ulcer. The heterogeneity of the compression systems and the measures used to evaluate HRQoL make it a challenge to interpret the overall evidence. Further studies should strive for homogeneity in design, interventions and comparators to enhance both internal and external validity.
<P>PROBLEM TO BE SOLVED: To form a personal storage medium storing medical examination information, which is delivered to an examinee and can be carried by the examinee.  <P>SOLUTION: A medical information computerization system comprises a medical examination system 6 including a medical examination information database 7, an image server 8 including an image database 9, and a CD-R formation system 1. The CD-R formation system 1 includes the editing device 10 and a CD-R writer 30, and the editing device 10 includes an editing database 20. The editing device 10 fetches medical examination information to be written to a CD-R for an examinee for which the CD-R is formed from the medical examination information given from the system 6. The editing device 10 acquires an inspection image (image data) relevant to the medical examination information for the examinee from the image server 8, edits these medical examination information and image data to a format to be written to the CD-R with various pieces of fixed information, and transmits the edited data to the CD-R writer 30.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
An additive for a skin care composition, wherein the additive comprises a complex of mangiferin with β-cyclodextrin or a β-cyclodextrin derivative is provided. Preferably the β-cyclodextrin derivative is selected from hydroxypropyl-β-cyclodextrin, sulfobutylether β-cyclodextrin and mono(6-ethylene-diamino-6-deoxy)-β-cyclodextrin. The mangiferin-β-cyclodextrin complex preferably has a stoichiometric ratio of 1:1. The mangiferin-β-cyclodextrin additive is preferably for the prevention of UV-induced mitochondrial DNA (mtDNA) damage. A skin care composition comprising a mangiferin-β-cyclodextrin additive is also outlined wherein preferably the additive is included in the composition such that the concentration of the mangiferin in the composition is from 1 to 10% (w/w). preferably the composition is in the form of an emulsion where the mangiferin-β-cyclodextrin complex is in an aqueous phase. The skin care composition may further comprise at least one additional ingredient selected from an organic UV filter, an inorganic UV filter, an emulsifier, a suspending agent, a film former and a skin conditioner. A method of preparing a mangiferin-β-cyclodextrin additive is provided comprising: (i) preparing a solution of β-cyclodextrin or β-cyclodextrin derivative in water; (ii) adding mangiferin to the solution; (iii) allowing the complex to form at a temperature of between 30oC and 50oC for between 3 to 6 hours; and (iv) removing solids by filtration.
Wheat (Triticum aestivum) is a major staple crop worldwide, and its yields are significantly threatened by wheat powdery mildew (Blumeria graminis f. sp. tritici). Enhancing disease resistance in wheat is crucial for meeting global food demand. This study investigated the disease response in wheat, focusing on the bioactive small molecules salicylic acid (SA), pipecolic acid (Pip), and N-hydroxypipecolic acid (NHP), to provide new insights for molecular breeding. We found that endogenous levels of SA, Pip, and NHP significantly increased in infected plants, with Pip and NHP levels rising earlier than those of SA. Notably, the rate of increase of NHP was substantially higher than that of SA. The gene expression levels of SARD1 and CBP60g, which are transcription factors for SA, Pip, and NHP biosynthesis, increased significantly during the early stages of infection. We also found that during the later stages of infection, the expression of ALD1, SARD4, and FMO1, which encode enzymes for Pip and NHP biosynthesis, dramatically increased. Additionally, ICS1, which encodes a key enzyme involved in SA biosynthesis, also showed increased expression during the later stages of infection. The temporal changes in ICS1 transcription closely mirrored the behavior of endogenous SA levels, suggesting that the ICS pathway is the primary route for SA biosynthesis in wheat. In conclusion, our results suggest that the early accumulation of Pip and NHP cooperates with SA in the disease response against wheat powdery mildew infection.
SHAKE WELL BEFORE USING. Two drops topically in the eye(s) four times daily. In cases of bacterial infections, concomitant use of anti-infective agents is mandatory. Care should be taken not to discontinue therapy prematurely.

If signs and symptoms fail to improve after two days, the patient should be re-evaluated (SEE PRECAUTIONS).

The dosing of ECONOPRED and ECONOPRED Plus may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications.
Cerebral infarction: being ischemic thrombosis cerebral infarction, and artery sclerosis is that high blood pressure, cholesterol and blood viscosity are high, and on esterification calmness tube wall, patch blocks blood road, causes vessel wall damage and the bent obstacle of row.Change spot thrombolysis Chinese medicine: 35 kinds of safflower, Radix Angelicae Sinensis, full worm, arisaema cum bile, chrysanthemum, sophora flower, Radix Salviae Miltiorrhizae, Semen sesami nigrum, dilute Xian, Semen sesami nigrum, Radix Curcumae, Rhizoma Chuanxiong, ramulus mori etc..Main ingredient: 1. triterpenoid saponin: reducing blood pressure, clearing gallbladder sterol and concentration, reduces cholesterol/cephalin coefficient, and lipid increases improvement.2. saponin: preventing the esterification of cholesterol for plasma lipoprotein and its deposited on vascular wall.3. soybean brass: increasing vascular flow, reduced to internal artery vascular resistence, improve Brain circlulation.4. oleanolic acid: inhibiting vasomotor center to generate decompression by vagus nerve.5. general flavone: having resistance, vasodilator decompression to capillary.6. three-iron saponin(e: having central nervous system effect, antitumor, anti-inflammatory, antibacterial, resists strongly fragrant, calm, hypnosis, analgesia at refresh memory.
Ginsenoside Rb1 (Rb1), an active component isolated from traditional Chinese medicine Ginseng, is beneficial to many cardiovascular diseases. However, whether it can protect against doxorubicin induced cardiotoxicity (DIC) is not clear yet. In this study, we aimed to investigate the role of Rb1 in DIC. Mice were injected with a single dose of doxorubicin (20 mg/kg) to induce acute cardiotoxicity. Rb1 was given daily gavage to mice for 7 days. Changes in cardiac function, myocardium histopathology, oxidative stress, cardiomyocyte mitochondrion morphology were studied to evaluate Rb1's function on DIC. Meanwhile, RNA-seq analysis was performed to explore the potential underline molecular mechanism involved in Rb1's function on DIC. We found that Rb1 treatment can improve survival rate and body weight in Dox treated mice group. Rb1 can attenuate Dox induced cardiac dysfunction and myocardium hypertrophy and interstitial fibrosis. The oxidative stress increase and cardiomyocyte mitochondrion injury were improved by Rb1 treatment. Mechanism study found that Rb1's beneficial role in DIC is through suppressing of autophagy and ferroptosis. This study shown that Ginsenoside Rb1 can protect against DIC by regulating autophagy and ferroptosis.
This study will have two asthma phenotypes and one control population. Patients will be recruited from the WTC EHC = 30 with WTC dust cloud exposure, patients will be recruited from the NYUBAR (n=30) and have asthma as defined by NIH guidelines, and control patients will be recruited from the NYUBAR (n=30) and will have no respiratory sx, no asthma diagnosis, or no WTC dust exposure.

The study will entail two to three visits. On visit 1 (V1) all individuals will sign informed consent to participate in the study under an NYU IRB approved protocol. A questionnaire will be completed with standardized questions that include information on WTC exposures, demographics, presence and severity of respiratory symptoms, tobacco history and past medical history. Individuals will undergo spirometry with inhaled bronchodilator. Individuals will undergo methacholine challenge test (visit 1a) if they have normal spirometry or no bronchial hyperresponsiveness. On visit 2, individuals will return to undergo ENO, EBC and spirometry with pre and post bronchodilator maneuvers and induced sputum. Blood will be obtained for CBC with differential cell count, and assessment of total IgE and allergen-specific IgE. Blood will also be stored for future analysis of inflammatory markers. Based on experience, there have been individuals unable to produce enough sputum and thus yield too small a number of cells. These individuals are excluded from data analysis. In addition, there will also be subjects who are able to produce sputum and return for repeat sputum testing.
Subjects will be allocated to three cohorts of 10 subjects each receiving one single vaccine injection administered as an i.m. injection.
The fitbit Ultra was used to provide real-time feedback on physical activity. An experienced physiotherapist contacted the subjects 3 times a week to receive information about the amount of steps from the previous days. In agreement with the patient, a new goal for the coming weeks was set and patients were motivated to achieve their individual goal.
The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD.
Patients receive oral bicalutamide and oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.